in-EV
 |
Website:https://in-ev.com |
|||||||||||||||||||||||||
in-EV SAS is a subsidiary of Ciloa SAS, a pioneer in exosome R&D with over 13 years' experience in bioengineering exosomes to develop a new generation of vaccines and therapeutic vectors. This exceptional experience has unlocked most exosome bottlenecks, leading to a pipeline of bioengineered EVs with over 130 membrane or cytosolic proteins, a dozen vaccine candidates and several therapeutic vectors for metabolic diseases and oncology. Learn more
|
||||||||||||||||||||||||||
